melatonin has been researched along with Heart Diseases in 25 studies
Heart Diseases: Pathological conditions involving the HEART including its structural and functional abnormalities.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study evaluates the development of edema, the change in the AQP3, AQP4, p53 and Bax gene expressions, and the protective effects of melatonin in rat hearts administered with cisplatin." | 8.02 | The role of AQP3 and AQP4 channels in cisplatin-induced cardiovascular edema and the protective effect of melatonin. ( Adali, Y; Karakilic, E; Koral, L; Ovali, MA; Tufekcioglu, NK; Uzun, M, 2021) |
| "Melatonin is a hormone produced by the pineal gland, and it has extensive beneficial effects on various tissue and organs; however, whether melatonin has any effect on cardiac fibrosis in the pathogenesis of diabetic cardiomyopathy (DCM) is still unknown." | 7.96 | Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1/miR-141-mediated NLRP3 inflammasome and TGF-β1/Smads signaling in diabetic cardiomyopathy. ( Che, H; Dong, R; Li, H; Li, Y; Liu, Y; Lv, J; Sahil, A; Wang, L; Wang, Y; Xue, H; Yang, Z, 2020) |
| "In this study, we found that melatonin protected against sepsis-induced cardiac dysfunction by regulating apoptosis and autophagy via activation of SIRT1 in mice." | 7.91 | Melatonin protects against sepsis-induced cardiac dysfunction by regulating apoptosis and autophagy via activation of SIRT1 in mice. ( He, BM; Peng, ZY; Qiao, JF; Wu, Y; Zhang, WX, 2019) |
| "Fibrosis is a common occurrence following organ injury and failure." | 6.53 | Melatonin: the dawning of a treatment for fibrosis? ( Deng, C; Di, S; Fan, C; Hu, W; Jiang, S; Lv, J; Ma, Z; Reiter, RJ; Yan, X; Yang, Y, 2016) |
| "Melatonin was administrated to rats intraperitoneally (30 mg/kg)." | 5.43 | Melatonin attenuates sepsis-induced cardiac dysfunction via a PI3K/Akt-dependent mechanism. ( An, R; Li, H; Liu, H; Shen, G; Sun, L; Xi, C; Zhang, S; Zhao, L, 2016) |
| "The present study evaluates the development of edema, the change in the AQP3, AQP4, p53 and Bax gene expressions, and the protective effects of melatonin in rat hearts administered with cisplatin." | 4.02 | The role of AQP3 and AQP4 channels in cisplatin-induced cardiovascular edema and the protective effect of melatonin. ( Adali, Y; Karakilic, E; Koral, L; Ovali, MA; Tufekcioglu, NK; Uzun, M, 2021) |
| "Melatonin is a hormone produced by the pineal gland, and it has extensive beneficial effects on various tissue and organs; however, whether melatonin has any effect on cardiac fibrosis in the pathogenesis of diabetic cardiomyopathy (DCM) is still unknown." | 3.96 | Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1/miR-141-mediated NLRP3 inflammasome and TGF-β1/Smads signaling in diabetic cardiomyopathy. ( Che, H; Dong, R; Li, H; Li, Y; Liu, Y; Lv, J; Sahil, A; Wang, L; Wang, Y; Xue, H; Yang, Z, 2020) |
| "In this study, we found that melatonin protected against sepsis-induced cardiac dysfunction by regulating apoptosis and autophagy via activation of SIRT1 in mice." | 3.91 | Melatonin protects against sepsis-induced cardiac dysfunction by regulating apoptosis and autophagy via activation of SIRT1 in mice. ( He, BM; Peng, ZY; Qiao, JF; Wu, Y; Zhang, WX, 2019) |
| "Melatonin is a neurohormone released by the pineal gland." | 2.82 | Melatonin and the Brain-Heart Crosstalk in Neurocritically Ill Patients-From Molecular Action to Clinical Practice. ( Bekała, A; Bielacz, M; Biernawska, J; Bohatyrewicz, R; Dabrowski, W; Jaroszyński, A; Kotfis, K; Płotek, W; Siwicka-Gieroba, D; Sołek-Pastuszka, J, 2022) |
| "Fibrosis is a common occurrence following organ injury and failure." | 2.53 | Melatonin: the dawning of a treatment for fibrosis? ( Deng, C; Di, S; Fan, C; Hu, W; Jiang, S; Lv, J; Ma, Z; Reiter, RJ; Yan, X; Yang, Y, 2016) |
| " MEL weakened the toxic effects of DOX on the cardiac tissue and it is shown histologically." | 1.62 | Effects of Melatonin and Adrenomedullin in Reducing the Cardiotoxic Effects of Doxorubicin in Rats. ( Bahceci, SA; Durdagi, G; Oyar, EO; Ozbek, M; Pehlivan, DY, 2021) |
| "Melatonin is a neuroendocrine hormone and has been found to be protective in heart disease." | 1.51 | Network-based transcriptomic analysis reveals novel melatonin-sensitive genes in cardiovascular system. ( Hu, F; Li, K; Liu, FF; Wei, Q; Xiong, W, 2019) |
| "Melatonin was administrated to rats intraperitoneally (30 mg/kg)." | 1.43 | Melatonin attenuates sepsis-induced cardiac dysfunction via a PI3K/Akt-dependent mechanism. ( An, R; Li, H; Liu, H; Shen, G; Sun, L; Xi, C; Zhang, S; Zhao, L, 2016) |
| "Melatonin is a potent antioxidant molecule with a capacity to protect tissues from damage caused by oxidative stress." | 1.35 | Melatonin delivery in solid lipid nanoparticles: prevention of cyclosporine A induced cardiac damage. ( Demartini, G; Fraschini, F; Gasco, MR; Musicanti, C; Reiter, RJ; Rezzani, R; Rodella, LF, 2009) |
| "Melatonin treatment lowered the nitrite/nitrate concentrations, while increasing the GSH levels, which exceeded the levels in epirubicin+melatonin-treated rats." | 1.34 | Melatonin protects against epirubicin-induced cardiotoxicity. ( Bukan, N; Cam, M; Comunoglu, C; Ercan, F; Guven, A; Yavuz, O, 2007) |
| " However, there are serious toxic effects on the cardiovascular system, which limits the application of the drug." | 1.31 | Melatonin protects against cardiac toxicity of doxorubicin in rat. ( Ho, S; Qian, ZM; Tang, PL; Xu, MF, 2001) |
| "Melatonin was administered subcutaneously before and after every injection of a cytostatic drug at a dose of 10 mg/kg b." | 1.31 | Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat. ( Dziegiel, P; Jethon, Z; Rabczyński, J; Sopel, M; Suder, E; Surowiak, P; Zabel, M, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (24.00) | 29.6817 |
| 2010's | 11 (44.00) | 24.3611 |
| 2020's | 8 (32.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koral, L | 1 |
| Ovali, MA | 1 |
| Tufekcioglu, NK | 1 |
| Karakilic, E | 1 |
| Adali, Y | 1 |
| Uzun, M | 1 |
| Bekała, A | 1 |
| Płotek, W | 1 |
| Siwicka-Gieroba, D | 1 |
| Sołek-Pastuszka, J | 1 |
| Bohatyrewicz, R | 1 |
| Biernawska, J | 1 |
| Kotfis, K | 1 |
| Bielacz, M | 1 |
| Jaroszyński, A | 1 |
| Dabrowski, W | 1 |
| Akgun-Unal, N | 1 |
| Ozyildirim, S | 1 |
| Unal, O | 1 |
| Baltaci, SB | 1 |
| Mogulkoc, R | 1 |
| Baltaci, AK | 1 |
| Ziegler, KA | 1 |
| Ahles, A | 1 |
| Dueck, A | 1 |
| Esfandyari, D | 1 |
| Pichler, P | 1 |
| Weber, K | 1 |
| Kotschi, S | 1 |
| Bartelt, A | 1 |
| Sinicina, I | 1 |
| Graw, M | 1 |
| Leonhardt, H | 1 |
| Weckbach, LT | 1 |
| Massberg, S | 1 |
| Schifferer, M | 1 |
| Simons, M | 1 |
| Hoeher, L | 1 |
| Luo, J | 1 |
| Ertürk, A | 1 |
| Schiattarella, GG | 1 |
| Sassi, Y | 1 |
| Misgeld, T | 1 |
| Engelhardt, S | 1 |
| Che, H | 1 |
| Wang, Y | 1 |
| Li, H | 2 |
| Li, Y | 1 |
| Sahil, A | 1 |
| Lv, J | 2 |
| Liu, Y | 1 |
| Yang, Z | 1 |
| Dong, R | 1 |
| Xue, H | 1 |
| Wang, L | 1 |
| Simko, F | 1 |
| Hrenak, J | 1 |
| Dominguez-Rodriguez, A | 2 |
| Reiter, RJ | 3 |
| Durdagi, G | 1 |
| Pehlivan, DY | 1 |
| Oyar, EO | 1 |
| Bahceci, SA | 1 |
| Ozbek, M | 1 |
| Pi, QZ | 1 |
| Wang, XW | 1 |
| Jian, ZL | 1 |
| Chen, D | 1 |
| Zhang, C | 1 |
| Wu, QC | 1 |
| Ballyuzek, MF | 1 |
| Mashkova, MV | 1 |
| Arutjunyan, AV | 1 |
| Duke, VA | 1 |
| Zhang, WX | 1 |
| He, BM | 1 |
| Wu, Y | 1 |
| Qiao, JF | 1 |
| Peng, ZY | 1 |
| Li, K | 1 |
| Hu, F | 1 |
| Xiong, W | 1 |
| Wei, Q | 1 |
| Liu, FF | 1 |
| Musa, AE | 1 |
| Shabeeb, D | 1 |
| Jafari-Vayghan, H | 1 |
| Saleh-Ghadimi, S | 1 |
| Maleki, V | 1 |
| Moludi, J | 1 |
| Alizadeh, M | 1 |
| Yeung, HM | 1 |
| Hung, MW | 1 |
| Lau, CF | 1 |
| Fung, ML | 1 |
| An, R | 1 |
| Zhao, L | 1 |
| Xi, C | 1 |
| Shen, G | 1 |
| Liu, H | 1 |
| Zhang, S | 1 |
| Sun, L | 1 |
| Hu, W | 1 |
| Ma, Z | 1 |
| Jiang, S | 1 |
| Fan, C | 1 |
| Deng, C | 1 |
| Yan, X | 1 |
| Di, S | 1 |
| Yang, Y | 1 |
| Rezzani, R | 1 |
| Rodella, LF | 1 |
| Fraschini, F | 1 |
| Gasco, MR | 1 |
| Demartini, G | 1 |
| Musicanti, C | 1 |
| Saeidi, M | 1 |
| Sobhani, R | 1 |
| Movahedi, M | 1 |
| Alsaeidi, S | 1 |
| Samani, RE | 1 |
| Mukherjee, R | 1 |
| Banerjee, S | 1 |
| Joshi, N | 1 |
| Singh, PK | 1 |
| Baxi, D | 1 |
| Ramachandran, AV | 1 |
| Abreu-Gonzalez, P | 1 |
| Lavi, R | 1 |
| Lavi, S | 1 |
| Guven, A | 1 |
| Yavuz, O | 1 |
| Cam, M | 1 |
| Ercan, F | 1 |
| Bukan, N | 1 |
| Comunoglu, C | 1 |
| Xu, MF | 1 |
| Ho, S | 1 |
| Qian, ZM | 1 |
| Tang, PL | 1 |
| Dziegiel, P | 1 |
| Jethon, Z | 1 |
| Suder, E | 1 |
| Sopel, M | 1 |
| Rabczyński, J | 1 |
| Surowiak, P | 1 |
| Zabel, M | 1 |
| Liu, X | 1 |
| Chen, Z | 1 |
| Chua, CC | 1 |
| Ma, YS | 1 |
| Youngberg, GA | 1 |
| Hamdy, R | 1 |
| Chua, BH | 1 |
4 reviews available for melatonin and Heart Diseases
| Article | Year |
|---|---|
Melatonin and the Brain-Heart Crosstalk in Neurocritically Ill Patients-From Molecular Action to Clinical Practice.
Topics: Antioxidants; Brain; Brain Injuries; Brain Injuries, Traumatic; Heart Diseases; Humans; Melatonin | 2022 |
Radiation-Induced Heart Diseases: Protective Effects of Natural Products.
Topics: Biological Products; Caffeic Acids; Curcumin; Drug Combinations; Drugs, Chinese Herbal; Guaiacol; He | 2019 |
The effects of melatonin on neurohormonal regulation in cardiac cachexia: A mechanistic review.
Topics: Cachexia; Forkhead Box Protein O1; Heart Diseases; Humans; Insulin-Like Growth Factor I; Melatonin; | 2019 |
Melatonin: the dawning of a treatment for fibrosis?
Topics: Animals; Extracellular Matrix; Fibrosis; Heart Diseases; Humans; Kidney Diseases; Liver Cirrhosis; M | 2016 |
21 other studies available for melatonin and Heart Diseases
| Article | Year |
|---|---|
The role of AQP3 and AQP4 channels in cisplatin-induced cardiovascular edema and the protective effect of melatonin.
Topics: Animals; Aquaporin 3; Aquaporin 4; Cardiotonic Agents; Cisplatin; Edema; Heart Diseases; Melatonin; | 2021 |
The effects of resveratrol and melatonin on cardiac dysfunction in diabetic elderly female rats.
Topics: Animals; Diabetes Mellitus, Experimental; Female; Heart Diseases; Melatonin; Papillary Muscles; Rats | 2023 |
Immune-mediated denervation of the pineal gland underlies sleep disturbance in cardiac disease.
Topics: Animals; Circadian Rhythm; Fibrosis; Heart Diseases; Humans; Macrophages; Melatonin; Mice; Pineal Gl | 2023 |
Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1/miR-141-mediated NLRP3 inflammasome and TGF-β1/Smads signaling in diabetic cardiomyopathy.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Fibrosis; Gene Ex | 2020 |
Melatonin as a putative protection against myocardial injury in COVID-19 infection.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Heart Diseases; Humans; Melatonin; Pandemics; Pne | 2020 |
Effects of Melatonin and Adrenomedullin in Reducing the Cardiotoxic Effects of Doxorubicin in Rats.
Topics: Action Potentials; Adrenomedullin; Animals; Anti-Inflammatory Agents; Antioxidants; Cardiotoxicity; | 2021 |
Melatonin Alleviates Cardiac Dysfunction Via Increasing Sirt1-Mediated Beclin-1 Deacetylation and Autophagy During Sepsis.
Topics: Acetylation; Animals; Autophagy; Beclin-1; Cells, Cultured; Disease Models, Animal; Heart Diseases; | 2021 |
[Melatonin as a marker of the grade of cardiac disorders during cachexia development in oncological patients of different ages].
Topics: Adult; Age Factors; Aged; Biomarkers; Cachexia; False Positive Reactions; Heart Diseases; Humans; Me | 2017 |
Melatonin protects against sepsis-induced cardiac dysfunction by regulating apoptosis and autophagy via activation of SIRT1 in mice.
Topics: Animals; Apoptosis; Autophagy; Cardiotonic Agents; Heart; Heart Diseases; Male; Melatonin; Mice, Inb | 2019 |
Network-based transcriptomic analysis reveals novel melatonin-sensitive genes in cardiovascular system.
Topics: Cardiovascular System; Databases, Genetic; Gene Expression Profiling; Gene Regulatory Networks; Hear | 2019 |
Cardioprotective effects of melatonin against myocardial injuries induced by chronic intermittent hypoxia in rats.
Topics: Animals; Antioxidants; Biomarkers; Cardiotonic Agents; Chronic Disease; Cytokines; Gene Expression R | 2015 |
Melatonin attenuates sepsis-induced cardiac dysfunction via a PI3K/Akt-dependent mechanism.
Topics: Animals; Antioxidants; Blotting, Western; Disease Models, Animal; Echocardiography; Enzyme-Linked Im | 2016 |
Melatonin delivery in solid lipid nanoparticles: prevention of cyclosporine A induced cardiac damage.
Topics: Analysis of Variance; Animals; Apoptosis; Cyclosporine; Drug Carriers; Heart Diseases; Immunosuppres | 2009 |
Effect of melatonin in the prevention of postoperative pericardial adhesion formation.
Topics: Animals; Cardiac Surgical Procedures; Dogs; Heart Diseases; Melatonin; Pericardium; Tissue Adhesions | 2009 |
A combination of melatonin and alpha lipoic acid has greater cardioprotective effect than either of them singly against cadmium-induced oxidative damage.
Topics: Animals; Antioxidants; Ascorbic Acid; Biomarkers; Cadmium Chloride; Drug Synergism; Drug Therapy, Co | 2011 |
Melatonin: Still a forgotten antioxidant.
Topics: Antioxidants; Cardiotonic Agents; Heart Diseases; Humans; Melatonin | 2011 |
Melatonin and myocardial protection.
Topics: Antioxidants; Cardiotonic Agents; Heart Diseases; Humans; Melatonin | 2011 |
Melatonin protects against epirubicin-induced cardiotoxicity.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Drug Therapy, Combination; Epirubicin; Extracell | 2007 |
Melatonin protects against cardiac toxicity of doxorubicin in rat.
Topics: Animals; Antineoplastic Agents; Doxorubicin; Heart; Heart Diseases; Hemodynamics; Lipid Peroxidation | 2001 |
Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Daunorubicin; Doxorubicin; Drug Interactions; He | 2002 |
Melatonin as an effective protector against doxorubicin-induced cardiotoxicity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Body Weight; Cardiotonic Agents; Creatine Kinase; Cytopro | 2002 |